Oct 21

October 10, 2011 4:01 AM
By Craig Trudell

Oct. 10 (Bloomberg) — Automotive companies, sold short by more U.S. investors than any industry except services, are too cheap when weighed against record vehicle sales and provide opportunities for bets against a financial collapse.

Short interest, a measure of bets that stock prices will fall, in automakers and parts suppliers increased by 50 percent in September to 1.7 percent of total shares, according to researcher Data Explorers. The ratio of long to short interest deteriorated to the lowest this year at the end of last month.

Global auto sales are on pace to reach a record 74.6 million this year, J.D. Power & Associates says. Deliveries in the U.S. accelerated in September to the fastest pace since April, and sales in China may rise to 17.7 million, the most in any country ever. At the same time, the 28-member Bloomberg World Auto Manufacturers Index lost 21 percent through Oct. 7.

“These stocks have gotten hammered and are starting to represent good value,” Harry Rady, who oversees $260 million as chief executive officer of hedge fund Rady Asset Management LLC. “Obviously it hinges on which way the economy goes, but if anything even a little better than a very dire scenario materializes, these stocks could rock.”

Global monetary-policy makers, including the Federal Reserve and European Central Bank, are expanding efforts to support their economies as the euro region’s sovereign-debt crisis roils markets. Morgan Stanley, which rates the U.S. auto sector “attractive,” said in a report last week that “trading auto stocks in this macro environment is like playing ping-pong in a hurricane.”

‘Real Fears’

“You can’t have this much fear about sovereign risk, and mentioning U.S. economy and depression so frequently, without creating real fears for the real economy, and that hits auto sales, mix and pricing,” Adam Jonas, Morgan Stanley’s New York- based analyst, said in a phone interview. “It’s confusing investors because the bottom-up data does look pretty good.”

General Motors Co. may earn $7.83 billion in net income this year, a 27 percent gain from 2010, according to four analysts surveyed by Bloomberg. Ford Motor Co.’s profit may rise 16 percent from a year earlier to $7.56 billion, the average of six estimates. Shares of Detroit-based GM have plunged 40 percent this year, while Dearborn, Michigan-based Ford lost 36 percent.

“There are a lot of metrics in this sector that your value investor would look at and say ‘Wow, that’s pretty cheap,’” said Dennis Wassung, who helps oversee about $500 million at Cabot Money Management Inc. in Salem, Massachusetts.

GM Shorts

Short interest in GM climbed to 2.5 percent of total shares, about one-fifth of lendable supply, London-based Data Explorers said last week in a report. Ford’s short interest was 3 percent of total shares, the researcher said.

GM’s pension liabilities “no question” became investors’ biggest concern about the Detroit-based company during the past quarter, Morgan Stanley’s Jonas said.

The company’s U.S. pension fund, which faced a $12.4 billion shortfall at the end of 2010, may finish the year underfunded by $18.5 billion, he estimates. The liability will rise even as GM makes an estimated $6.1 billion in cash and $1.4 billion in stock contributions this year, Morgan Stanley estimates.

“That’s a huge offset to the very cash-rich balance sheet they have,” Jonas said. The pension liability “competes with what was until recently hopes of a cash-return story from GM. That’s being put to bed.”

Ford’s U.S. pension shortfall may climb to $11.6 billion this year, from $6.7 billion at the end of 2010, Jonas said. Morgan Stanley estimates the Dearborn, Michigan-based company may contribute $1.5 billion to its U.S. plans this year. Investors also are concerned about GM and other rivals closing a gap in product quality and “freshness” to Ford, Jonas said.

Ford’s Product

“The competition is going to catch up over the next two years,” he said. “It won’t be as much of an advantage. GM is replacing more product over the next two years.”

September U.S. auto sales gains exceeded analysts’ estimates, rising to a seasonally adjusted annualized rate of 13.1 million, according to Autodata Corp. The pace is the highest since April’s 13.2 million, when lost output caused by Japan’s tsunami started crimping supply of parts and cars.

The U.S. averaged annual sales of 16.8 million vehicles from 2000 to 2007, according to Woodcliff Lake, New Jersey-based Autodata.

Annual U.S. deliveries peaked at 17.4 million in 2000. China may pass that total for the first time, with sales increasing about 3 percent to 17.7 million in 2011, according to Westlake Village, California-based J.D. Power. China’s auto market may exceed 25 million annual light-vehicle sales by 2015, J.D. Power predicts.

China’s Growth

Regulators have moved to curb growth for China’s auto market this year by measures such as Beijing’s limits to the number of license plates available. Zhejiang Geely Holding Group Co. short interest peaked at 7.6 percent of total shares in August, almost all of the lendable supply, Data Explorers says.

“There’s a 10-year history there of substantial growth” in China’s auto market, said Cabot’s Wassung, whose fund holds shares of automaker Dongfeng Motor Co. “It’s not done. This year’s going to be a bit of a pause, but it’s likely that this trend of an emerging middle class that adds hundreds of millions of new consumers to the market is not over.”

Carlos Ghosn, chief executive officer of Renault SA and Nissan Motor Co., which has a Chinese venture with Dongfeng, said in an interview that investors are uncertain about the global economy and that moves in the share prices of his companies have been “extreme.”

“I am not particularly pessimistic, even though I don’t think we’re going to go through this very quickly,” Ghosn said in an Oct. 6 interview from Rio de Janeiro, where Nissan announced a new $1.4 billion auto plant in Brazil.

–With assistance from Alan Ohnsman in Los Angeles. Editors: Jamie Butters, Bill Koenig

May 5

04/19/2011
Bloomberg BusinessWeek
Lachapelle, Tara

Johnson & Johnson, reeling from more than 50 drug and device recalls since the start of 2010, is trying to recapture its younger self by digesting Synthes Inc.

Synthes, the largest maker of devices to treat bone fractures and trauma, has an operating margin of 35 percent, the highest among medical-products makers including J&J with market values of more than $5 billion, according to data compiled by Bloomberg. Synthes has increased the amount of net income generated per dollar of revenue for seven straight years to the best in the industry, while J&J’s profit margin declined in two of the past four years, the data show.

J&J, with almost $28 billion in cash at its disposal, is in talks to acquire Synthes, a $19.4-billion company with only $98 million in debt, as it seeks to revive its image after product recalls and lawsuits over failed artificial hips. The world’s second-biggest maker of health-care products would gain a device company with almost 50 percent of the trauma market. Synthes’s operating margins are 45 percent higher than Smith & Nephew Plc, which investors had speculated was a target for J&J.

“J&J had a severe challenge to its premier reputation given all the recalls,” said Michael Holland, who oversees more than $4 billion, including J&J shares, as chairman of Holland & Co. in New York. “This relatively bold step to buy a premier company is a significant move to regain their luster.”

Share Gains

J&J’s shares rose as much as 1 percent yesterday before closing down 0.2 percent at $60.46 on the New York Stock Exchange. That was still the third-best performance in the Dow Jones Industrial Average, which slid 1.1 percent as Standard & Poor’s cut its outlook on U.S. long-term debt to “negative.”

Synthes advanced 5.6 percent to 146.5 Swiss francs in Zurich yesterday to give it a market value of 17.4 billion Swiss francs ($19.4 billion). The West Chester, Pennsylvania-based company said in a statement that it’s in talks with J&J about a possible combination. Synthes doesn’t intend to provide more information until a definitive agreement is reached or talks are terminated, it said.

William Price, a spokesman for New Brunswick, New Jersey- based J&J, declined to comment in an e-mail.

Shares of J&J climbed 2.2 percent to $61.80 in pre-market trading at 8:26 a.m. New York time today after the company reported first-quarter earnings that beat the average estimate from analysts and raised its full-year forecast. Synthes gained 1.9 percent to 149.3 francs.

‘Change the Focus’

J&J is considering an acquisition of Synthes after product recalls cost the company $900 million in sales last year. J&J removed almost 200 million packages of Tylenol, Motrin and other over-the-counter medications tainted by nauseating odors or improper ingredients. Its DePuy unit has also withdrawn 93,000 hip implants that failed at higher-than-expected rates, forcing repeat surgeries.

After the company’s McNeil Consumer Healthcare unit was charged on March 10 with violating U.S. law, the Food & Drug Administration expanded oversight of three manufacturing plants for at least five years. The settlement doesn’t preclude future criminal charges, the agency said at the time.

“They want to change the focus of the conversation,” said Erik Gordon, a University of Michigan business professor in Ann Arbor who studies the biomedical industry. J&J is “probably thinking, ‘Let’s have the conversation be the potential upside of something,’” he said.

While Synthes and J&J may “fit together,” J&J should be focused on fixing its in-house recall problems, he said.

‘Great Margins’

Synthes had an operating margin of 35 percent in 2010, the best among 17 medical-product companies with market values greater than $5 billion, including J&J at 27 percent, data compiled by Bloomberg show. The company’s efficiency turning revenue into operating income also topped rivals specializing in medical instruments such as Minneapolis-based Medtronic Inc., St. Jude Medical Inc. in St. Paul, Minnesota, and Boston Scientific Corp. in Natick, Massachusetts.

Synthes improved its profit margin to 24.6 percent last year from 6.1 percent in 2003, the data show.

“They have great margins,” said Michael Liss, a Kansas City, Missouri-based portfolio manager at American Century Investments, which oversees $109 billion and owned about 7.8 million shares of J&J as of Dec. 31. “It only helps J&J’s margins overall.”

Synthes has attractive margins because it’s in the orthopedics market and has implemented efficiencies, Gilgian Eisner, a spokesman for the company in Solothurn, Switzerland, said yesterday.

Artificial Hips

J&J had looked at buying Smith & Nephew, Europe’s biggest marker of artificial hips and knees, a person familiar with the plan who declined to be identified because the discussions were private said in January. The U.K. device maker had a 16 percent profit margin in the 2010 calendar year. The London-based company declined 3 percent yesterday, the most since January, after Synthes confirmed it was in talks with J&J.

An acquisition of Synthes would push J&J’s share of the $5.5 billion orthopedic trauma market to 54 percent from about 5 percent, and boost earnings between 4 percent and 5 percent in each of the next three years, Larry Biegelsen, a Wells Fargo & Co. analyst in New York, said in a note to clients yesterday.

The trauma market will grow faster than replacement hips and knees, according to Biegelsen.

J&J’s share of the $9 billion spinal-care market would almost double, he said. The company may have to divest some of Synthes’s spine business, according to Lisa Bedell Clive, a London-based analyst with Sanford C. Bernstein & Co.

‘Called Into Question’

Prices for Synthes’s trauma devices may succumb to the pressure that has narrowed margins for other medical devices, according to Michael Weinstein, a JPMorgan Chase & Co. analyst in New York.

The sustainability of Synthes’s profits “has been and should be called into question,” he wrote in a note yesterday.

Synthes’s exclusive arrangement with the Swiss AO Foundation may draw antitrust scrutiny from U.S. regulators, Bernstein’s Clive said. The non-profit teaches courses for surgeons using only Synthes products, leading to many becoming Synthes customers, she said.

Like J&J, Synthes has also grappled with product recalls. After reports that its Synex II Central Body components had failed in six people, leading to pain and loss of height for some, Synthes recalled the spinal implants in 2009.

Credit Ratings

The company was also ordered to sell its Norian unit, which pleaded guilty in November to one felony and 110 misdemeanor counts for conducting an unauthorized trial of its bone-mending cement products. Three patients died, according to the U.S. Justice Department.

J&J built up $19.4 billion in cash and near cash items and $8.3 billion in short-term investments as of the end of last year that could be tapped for acquisitions, compared with $16.8 billion in total debt, according to data compiled by Bloomberg.

The maker of health-care products is one of only four U.S. companies to have the top credit rating from both Standard & Poor’s and Moody’s Investors Service. Irving, Texas-based Exxon Mobil Corp.; Microsoft Corp. of Redmond, Washington; and Automatic Data Processing Inc. in Roseland, New Jersey, are the others, data compiled by Bloomberg show.

J&J is also ranked AAA in Bloomberg’s Company Credit Ratings, which analyze borrowers based on indebtedness, profitability and other financial ratios. Even if J&J added long-term debt equal to the current market value of Synthes, it would still have a rating of A2L, the fourth-highest investment grade level. J&J’s combined cash and short-term investments outstrip the market capitalization of Synthes by about $8.2 billion, the data show.

Biggest Deal

Synthes, which is not rated by S&P or Moody’s, had total debt of $98.4 million at the end of last year, compared with $736.6 million in cash and near-cash items and $1.25 billion in short-term investments, data compiled by Bloomberg show.

An acquisition of Synthes for about $20 billion would be the biggest deal in J&J’s 125-year history, surpassing the $16.6 billion purchase of New York-based Pfizer Inc.’s consumer health care business in 2006. Pfizer is the world’s largest maker of medical products by sales.

“J&J is what it is. It’s a big powerhouse,” said Harry Rady, who oversees $270 million as chief executive officer of Rady Asset Management LLC, a hedge fund in La Jolla, California. “They could choose to allocate resources to fight all these small battles, or they could make a transformational acquisition like this to really change the face of the company.”

Overall, there have been 7,336 deals announced globally this year, totaling $713.1 billion, a 29 percent increase from the $553.3 billion in the same period in 2010, according to data compiled by Bloomberg.

Original Article - http://www.bloomberg.com/news/2011-04-19/j-j-synthes-merger-obscures-product-recalls-in-instant-makeover-real-m-a.html?cmpid=yhoo

Mar 4

Originally posted on Business Week
3/3/2011
Rita Nazareth

Warren Buffett has a cash hoard of almost $40 billion and wants to spend it on major acquisitions. The “elephant gun has been reloaded, and my trigger finger is itchy,” the 80-year-old chairman of Berkshire Hathaway (BRK.A) said in his annual letter to shareholders on Feb. 26.

Buffett typically prefers “simple” businesses with pretax profit exceeding $75 million, “consistent” earning power, and “good” returns on equity while employing little or no debt, he says in his report. He has shifted his takeover strategy as Berkshire focuses on “capital intensive businesses” that require investment in infrastructure and equipment, such as power producers and railroads. Investors such as Buffett prefer to buy companies when their valuations are low by historical standards. Last year he made his largest purchase, paying $26.5 billion for Burlington Northern Sante Fe railway. Buffett didn’t respond to a request for comment.

General Dynamics (GD), the maker of Gulfstream business jets and Abrams tanks; Exelon (EXC), the biggest U.S. nuclear power generator; and Archer Daniels Midland (ADM), the world’s biggest grain processor, are among 45 companies that meet the acquisition criteria listed in Buffett’s annual letter, according to data compiled by Bloomberg. “He’s probably looking for something along those lines,” says Barry James, who oversees $2.5 billion as president of James Investment Research in Xenia, Ohio. “Obviously we’re going to need defense, energy, and agriculture.”

Buffett owned a stake in General Dynamics more than a decade ago. Its net income rose 19 percent in the fourth quarter as demand for Gulfstream jets rose, and Chief Executive Officer Jay L. Johnson says the aerospace unit will increase sales at least 10 percent this year. Rob Doolittle, a spokesman for General Dynamics, declined to comment.

ADM could appeal to Buffett because it excels at transporting and storing food and grains, “a very difficult business to replicate,” says Brian M. Barish, president of Cambiar Investors in Denver. One thing that might deter Buffett is that in 1996 ADM agreed to pay a then-record $100 million antitrust fine after the government accused it of price fixing. Buffett’s son, Howard Buffett, joined ADM in 1992, serving as a director and head of investor relations. He resigned in July 1995 because he was unhappy with the company’s actions related to the investigation, The Wall Street Journal reported at the time. Roman Blahoski, a spokesman at ADM, declined to comment.

Exelon may be a target as Buffett looks to add to his stakes in utilities and power producers, according to Harry Rady, who oversees $270 million as CEO of Rady Asset Management in La Jolla, Calif. Exelon trades at 10.1 times earnings, compared with its five-year average of 14.7. “It’s out of favor,” says Rady. “That would be one that would be right up his alley.” Exelon spokesman Paul Elsberg also declined to comment.

Buffett could consider adding another insurer to his stable. Chubb (CB), Travelers (TRV), and Allstate (ALL) are all trading below their historical valuations based on book value, according to Paul Newsome, an analyst at Sandler O’Neill + Partners. Buying an insurer “definitely makes sense,” he says.

The bottom line: Bloomberg data show 45 companies that match up with the takeover goals Buffett outlined in his latest shareholder letter.

Original Article: http://www.businessweek.com/magazine/content/11_11/b4219043478685.htm

May 27

Despite an over two-month long surge in prices, there was little good news to maintain the market’s upward trend of bull-and-bearthe week ending on May 23rd. Advising caution, Harry Rady of Rady Asset Management remarked,

“Everything is overpriced. A very long, protracted recession is still very much alive.”

According to an article on “BradentonHerald.com” the week began on a positive note with stocks rallying on Monday. As the week progressed however, markets began a downward slide in response to several pieces of “not-so-good’ news which were announced during the week.

The federal government expects unemployment to reach as much as 9.6 percent, a much worse prediction than previously, and Standard and Poor’s may demote the British government from their present credit rating of AAA.
Hopes were thwarted when an early market gain on Friday ended the day with a total 15 point loss for the Dow Jones industrial average. As for the gains of the week, the major indicators all finished in the black, but only just.  The Dow squeeked ahead by 0.10 percent; S & P 500 index did slightly better with a 0.47 percent rise; and the Nasdaq did the best, almost finishing up by one whole percentage point at 0.71 percent increase in value.

The 10 week rally has lifted stocks by 30 percent since their 12-year low in March. With not much good news to continue to fuel this market surge stocks have been teetering and tottering without much gain in recent days.

The upcoming economic calendar is full of data such as reports of home sales levels, orders for manufactured products and indicators of consumer confidence, which should help determine which way this market is heading for the next few weeks.

Apr 22

dollarslyingaroundA general downturn in small capitalization stocks was posted last Monday, April 21st, 2009. In addition to smaller, regional banks crude oil prices, metals such as copper, and energy, and materials stocks all helped contribute to the reversal of what had been a six-week steady improvement in stock market results.

The Russell 2000, which is the index of small-capitalization stocks, posted a loss of 26.88 points, which is 5.61%, falling to a value of 240.85.

Improving consistently for the past 6 weeks, the Russell increased value by over 30% since its low at the beginning of March.

Credit markets have not been improving, even with the posted gains in small caps. Corporations just don’t seem to be signaling positive signs.

“Because these earnings haven’t been as bad as feared, it’s just provided an opportunity to put on more shorts. It’s just another head fake,” said Harry Rady of Rady Asset Management.

See the full article here:US Small Caps Close Lower On Slide For Regional Banks

Mar 15
Harry Rady on the internet
Posted by News in Business Week, Harry Rady, press on 03 15th, 2009| | 1 Comment »

Harry Rady has been at the forefront of the investment and hedge fund industries for a number of years, serving as CIO (Chief Investment Officer) in a number of companies, across varied fields and financial spheres. There is a lot of information available about Rady‘s past achievements as well as his current activities.

Visit Business Week’s site on the internet for some of the information about Harry Rady and the different companies he holds positions in.

Mar 10

EXECUTIVE PROFILE
Harry M. Rady

BACKGROUND
Harry M. Rady serves as Chief Investment Officer of ICW Group. Mr. Rady serves as Chief Investment Officer of American Assets, Inc…

CORPORATE HEADQUARTERS
11455 El Camino Real
San Diego, California 92130

United States

Phone: 800-877-1111
Fax: 858-350-2704
BOARD OF DIRECTORS MEMBERSHIPS

EDUCATION

View BusinessWeek.com page for the full Harry Rady information sheet.